McKesson and investment firm CD&R are in talks about acquiring Option Care Health in a deal valued at more than $5 billion, according to reports. Financial Times describes the transaction as nearing the $5 billion-plus mark, while other coverage places the potential price higher, around $5.8 billion.
Option Care Health provides infusion therapy services, including at-home and alternate site care, and is described as the largest independent provider of such services in the US. The transaction would take the company private, with at least one report saying closing is expected in the first half of 2027.
The outlets frame the deal as part of broader private equity and corporate buyout activity in healthcare services, including interest in companies viewed as undervalued. While reported figures differ slightly, all coverage centers on the same target, the same two buyers, and the same general timeline and privatization outcome.
